StockData
Lexaria Bioscience Corp. logo

Lexaria Bioscience Corp. (LEXX) stock

LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026Score 8/30
$4.03−0.46 (-10.24%)

Close on Nov 20, 2026Market cap $99.89MP/E –Yield –

Lexaria Bioscience free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Lexaria Bioscience's free cash flow for the twelve months ending May 31, 2026 was -$7.47M. For fiscal 2025 it was -$10.48M. The highest annual figure on record is -$663.95K in fiscal 2016.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Aug 31, 2025-$10.48M–
FY2024Aug 31, 2024-$5.00M–
FY2023Aug 31, 2023-$5.91M–
FY2022Aug 31, 2022-$4.93M–
FY2020Aug 31, 2020-$2.62M–
FY2019Aug 31, 2019-$3.65M–
FY2017Aug 31, 2017-$1.55M–
FY2016Aug 31, 2016-$663.95K–
FY2015Aug 31, 2015-$1.50M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026May 31, 2026-$1.64M–
Q2 FY2026CQ1 2026Feb 28, 2026-$2.20M–
Q1 FY2026CQ4 2025Nov 30, 2025-$984.10K–
Q4 FY2025CQ3 2025Aug 31, 2025-$2.64M–
Q3 FY2025CQ2 2025May 31, 2025-$3.58M–
Q2 FY2025CQ1 2025Feb 28, 2025-$1.50M–
Q1 FY2025CQ4 2024Nov 30, 2024-$2.75M–
Q4 FY2024CQ3 2024Aug 31, 2024-$1.93M–
Q3 FY2024CQ2 2024May 31, 2024-$1.27M–
Q2 FY2024CQ1 2024Feb 29, 2024-$619.61K–
Q1 FY2024CQ4 2023Nov 30, 2023-$1.18M–
Q4 FY2023CQ3 2023Aug 31, 2023-$1.62M–
Q3 FY2023CQ2 2023May 31, 2023-$1.79M–
Q2 FY2023CQ1 2023Feb 28, 2023-$1.24M–
Q1 FY2023CQ4 2022Nov 30, 2022-$1.27M–
Q4 FY2022CQ3 2022Aug 31, 2022-$1.18M–
Q3 FY2022CQ2 2022May 31, 2022-$1.27M–
Q2 FY2022CQ1 2022Feb 28, 2022-$1.28M–
Q1 FY2022CQ4 2021Nov 30, 2021-$1.21M–
Q1 FY2021CQ4 2020Nov 30, 2020-$809.53K–
Q4 FY2020CQ3 2020Aug 31, 2020-$639.35K–
Q1 FY2020CQ4 2019Nov 30, 2019-$555.08K–
Q4 FY2019CQ3 2019Aug 31, 2019-$746.13K–
Q3 FY2019CQ2 2019May 31, 2019-$1.30M–
Q2 FY2019CQ1 2019Feb 28, 2019-$921.57K–
Q1 FY2019CQ4 2018Nov 30, 2018-$687.15K–
Q4 FY2017CQ3 2017Aug 31, 2017-$353.34K–
Q3 FY2017CQ2 2017May 31, 2017-$603.50K–
Q2 FY2017CQ1 2017Feb 28, 2017-$488.09K–
Q1 FY2017CQ4 2016Nov 30, 2016-$100.99K–
Q4 FY2016CQ3 2016Aug 31, 2016-$260.77K–

More Lexaria Bioscience figures

See a number that looks wrong?